Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Tourmaline Bio, Inc.
Tourmaline Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights
August 08, 2024
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
Tickers
TRML
Tourmaline Bio Presents Phase 2 TRANQUILITY Study Design at American Society of Preventive Cardiology (ASPC) Congress 2024
August 02, 2024
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
Tickers
TRML
Tourmaline Bio Announces the Promotion of Ryan Robinson to Chief Financial Officer
June 27, 2024
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
Tickers
TRML
Tourmaline Bio to Present at the Jefferies Global Healthcare Conference
May 23, 2024
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
Tickers
TRML
Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial
May 16, 2024
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
Tickers
TRML
Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights
May 13, 2024
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
Tickers
TRML
Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
March 19, 2024
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
Tickers
TRML
Tourmaline Bio Announces Closing of $172.5 Million Public Offering of Common Stock, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
January 29, 2024
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
Tickers
TRML
Tourmaline Bio Announces Pricing of Public Offering of Common Stock
January 25, 2024
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
Tickers
TRML
Tourmaline Bio Announces Proposed Public Offering of Common Stock
January 24, 2024
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
Tickers
TRML
Tourmaline Bio Announces Expected Upcoming Key Milestones for the Clinical Development of TOUR006, a Long-Acting Subcutaneous Inhibitor of IL-6 with Best-in-Class Potential, in Thyroid Eye Disease (TED) and Atherosclerotic Cardiovascular Disease (ASCVD)
January 08, 2024
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
Tickers
TRML
Tourmaline Bio added to the NASDAQ Biotechnology Index
December 15, 2023
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
Tickers
NBI
TRML
Tourmaline Bio Appoints Dr. Clay Siegall as Chairman of the Board
December 14, 2023
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
Tickers
TRML
Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million
October 19, 2023
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
Tourmaline Bio Appoints Gerhard Hagn as SVP, Head of Commercial and Business Development
September 20, 2023
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
Tourmaline Bio Announces FDA Clearance of Investigational New Drug (IND) Application for TOUR006, an anti-IL-6 antibody with a differentiated profile for the treatment of thyroid eye disease (TED)
August 28, 2023
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.